Gilead: Near-Term Drug Filings Planned, But HIV Pressure Persists
This article was originally published in The Pink Sheet Daily
Executive Summary
Gilead expects to file for a new triple combination, Truvada plus Johnson & Johnson's TMC278, later this year, to extend the life of its HIV franchise.